Hansen L B, Larsen N E, Vestergård P
Psychopharmacology (Berl). 1981;74(4):306-9. doi: 10.1007/BF00432736.
Thirteen acute psychotic patients received continuous oral treatment with perphenazine for a period of 8 weeks. Blood samples for quantification of perphenazine, perphenazine sulphoxide and prolactin were drawn twice weekly. Simultaneously, the therapeutic outcome and the degree of extrapyramidal side effects were recorded. The following conclusions were made: 1. In accordance with results achieved in one of our earlier investigations, a high risk of provoking extrapyramidal side effects was associated with plasma levels of perphenazine exceeding about 3 nmol/l. 2. An excellent therapeutic outcome was associated with plasma concentrations of perphenazine above 1.5 nmol/l. 3. Plasma concentrations of perphenazine and prolactin were poorly correlated to each other (R = 0.49). 4. A significant correlation (R = 0.85) was shown between the scores for the Brief Psychiatric Rating Scale and the Comprehensive Psychopathological Rating Scale.
13名急性精神病患者接受了为期8周的奋乃静持续口服治疗。每周两次采集血样以定量奋乃静、奋乃静亚砜和催乳素。同时，记录治疗结果和锥体外系副作用的程度。得出以下结论：1. 根据我们早期一项研究的结果，奋乃静血浆水平超过约3 nmol/L时，引发锥体外系副作用的风险较高。2. 奋乃静血浆浓度高于1.5 nmol/L时，治疗效果极佳。3. 奋乃静血浆浓度与催乳素之间的相关性较差（R = 0.49）。4. 简明精神病评定量表得分与综合精神病理学评定量表得分之间存在显著相关性（R = 0.85）。
